Published in J Nucl Med on May 01, 2003
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24
Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging (2004) 1.48
Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging (2008) 1.14
Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol (2006) 1.06
Optimization of K-edge imaging with spectral CT. Med Phys (2012) 1.03
Additional value of integrated PET-CT in the detection and characterization of lung metastases: correlation with CT alone and PET alone. Eur Radiol (2006) 0.97
Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on (18)F-FDG PET-CT for radiotherapy treatment planning. Rep Pract Oncol Radiother (2012) 0.89
Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. Eur J Nucl Med Mol Imaging (2006) 0.88
PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging (2003) 0.86
Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol (2004) 0.85
Colorectal cancer: the role of PET/CT in recurrence. Cancer Imaging (2005) 0.84
Oral contrast medium in PET/CT: should you or shouldn't you? Eur J Nucl Med Mol Imaging (2005) 0.82
PET imaging in pediatric oncology. Pediatr Radiol (2004) 0.81
Optimisation of whole-body PET/CT scanning protocols. Biomed Imaging Interv J (2007) 0.81
PET-specific parameters and radiotracers in theoretical tumour modelling. Comput Math Methods Med (2015) 0.80
Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm. Eur J Nucl Med Mol Imaging (2008) 0.78
Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4-2008 image quality parameters. EJNMMI Res (2013) 0.78
Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations. Cancer Imaging (2007) 0.77
Morphology supporting function: attenuation correction for SPECT/CT, PET/CT, and PET/MR imaging. Q J Nucl Med Mol Imaging (2015) 0.76
Dose management in CT facility. Biomed Imaging Interv J (2007) 0.75
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med (2003) 7.64
The neural basis of altruistic punishment. Science (2004) 7.11
Feasibility of low-dose coronary CT angiography: first experience with prospective ECG-gating. Eur Heart J (2007) 4.03
Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging (2002) 3.01
Integrated PET/CT: current applications and future directions. Radiology (2006) 2.72
Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg (2005) 2.18
Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med (2004) 2.11
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys (2003) 2.10
Quantitative modeling of laser speckle imaging. Opt Lett (2006) 1.98
In vivo evidence for lactate as a neuronal energy source. J Neurosci (2011) 1.97
Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol (2006) 1.87
Imaging of chronic posttraumatic osteomyelitis. Eur Radiol (2001) 1.83
Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.79
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med (2004) 1.74
Integrated PET/CT for the assessment of coronary artery disease: a feasibility study. J Nucl Med (2005) 1.69
Assessment of 18F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiother Oncol (2006) 1.67
Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg (2004) 1.65
Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J (2004) 1.58
Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology (2004) 1.54
Initial staging of the neck in head and neck squamous cell carcinoma: a comparison of CT, PET/CT, and ultrasound-guided fine-needle aspiration cytology. Head Neck (2011) 1.54
Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.52
Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation. Eur Radiol (2002) 1.51
PET/CT: a new road map. Eur J Nucl Med Mol Imaging (2002) 1.50
Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med (2007) 1.48
PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology (2002) 1.43
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging (2015) 1.41
Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol (2002) 1.41
PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging (2002) 1.38
The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med (2002) 1.35
Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab (2002) 1.34
PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging (2012) 1.34
Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry (2011) 1.34
Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. Eur J Neurosci (2003) 1.32
Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med (2006) 1.32
Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med (2012) 1.27
F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med (2006) 1.26
FDG PET for differentiation of infection and aseptic loosening in total hip replacements: comparison with conventional radiography and three-phase bone scintigraphy. Radiology (2004) 1.26
Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol (2005) 1.25
Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology (2005) 1.25
Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology (2003) 1.22
High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology (2007) 1.22
Nonconscious formation and reactivation of semantic associations by way of the medial temporal lobe. Neuropsychologia (2003) 1.22
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg (2008) 1.21
Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology (2003) 1.16
Vascular graph model to simulate the cerebral blood flow in realistic vascular networks. J Cereb Blood Flow Metab (2009) 1.15
Global trends in hybrid imaging. Radiology (2010) 1.15
Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med (2007) 1.14
18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging (2010) 1.14
Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging (2009) 1.14
CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging (2002) 1.13
Intraductal oncocytic papillary neoplasm of the pancreas: a radio-pathological case study. JOP (2010) 1.13
CT attenuation correction for myocardial perfusion quantification using a PET/CT hybrid scanner. J Nucl Med (2004) 1.12
Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion -- report of six cases. Radiology (2002) 1.11
Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation (2003) 1.10
Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol (2002) 1.08
Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging (2006) 1.07
Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med (2002) 1.07
Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging (2007) 1.06
Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med (2010) 1.06
Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Radiology (2007) 1.06
Quantification of myocardial blood flow with 82Rb positron emission tomography: clinical validation with 15O-water. Eur J Nucl Med Mol Imaging (2012) 1.05
18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging (2003) 1.05
Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants. Eur J Nucl Med Mol Imaging (2002) 1.05
Red blood cell distribution in simplified capillary networks. Philos Trans A Math Phys Eng Sci (2010) 1.04
(18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging (2002) 1.03
Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate (2011) 1.03
Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? J Nucl Med (2014) 1.03
Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med (2004) 1.02
Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol (2002) 1.02
Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med (2008) 1.02
Metabotropic glutamate receptor mGluR5 is not involved in the early hemodynamic response. J Cereb Blood Flow Metab (2011) 1.01